Mental Health Clinics in Jefferson Hills, PA Accepting Medicare
2 Mental Health Clinics found. Showing 1 - 2
 1on1psychiatry Psychiatry & Neurology - Neurology Medicare: Not Enrolled in Medicare Practice Location: 1309 Mckinley Dr, Jefferson Hills, PA 15025 Phone: 412-951-7599 |
Laurelcare South/west Llc Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 1200 Brooks Ln Ste 210, Jefferson Hills, PA 15025 Phone: 412-458-6565 |
News Archive
Genous Bio-engineered R stent beneficial for patients not suitable for long term DAPT
OrbusNeich announced that clinical data presented at the Joint Intervention Meeting (JIM) 2010 in Rome provide further evidence that the company's Genous stent could be a treatment of choice for patients not suitable for long term dual antiplatelet therapy. The investigator initiated, 50 patient, multicenter study evaluated the safety of patients receiving only 10 days dual antiplatelet therapy undergoing stenting with the Genous Bio-engineered R stent. The primary endpoint was the absence of stent thrombosis or any occlusion within three months.
Health care votes haunt anti-abortion Dems; Republicans confront challenges with 'pledge'
Anti-abortion Democrats are facing stiff opposition in their bids for re-election because of their votes for health reform. Organizations like the Susan B. Anthony List and other anti-abortion groups are now attacking former allies who once sided with them on abortion. "Now, SBA List is engaged in a multimillion-dollar attack on its former allies, replete with bus tours and billboards alleging that members 'voted for taxpayer-funded abortion.'
Patient enrollment underway in Phase III trial program to evaluate amikacin inhalation solution
Bayer HealthCare Pharmaceuticals Inc. announced today that patient enrollment is underway in its global Phase III trial program to evaluate the efficacy and safety of adjunctive aerosolized BAY41-6551 versus aerosolized placebo in the treatment of intubated and mechanically ventilated patients with Gram-negative pneumonia receiving standard of care intravenous antibiotics.
Debiopharm receives AFSSAPS approval of CTA for Debio 0932 inhibitor, triggers milestone payment to Curis
Curis, Inc., announced today that its licensee Debiopharm S.A. has received approval from France's regulatory authority Agence Française de Securité Sanitaire des Produits de Santé (AFSSAPS) of a Clinical Trial Application (CTA) for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of Curis' and Debiopharm's August 2009 license agreement, Curis will receive an $8 million milestone payment from Debiopharm for the achievement of this development objective.
UB research yields neural crest cells from adult skin cells without genetic modification
A discovery, several years in the making, by a University at Buffalo research team has proven that adult skin cells can be converted into neural crest cells (a type of stem cell) without any genetic modification, and that these stem cells can yield other cells that are present in the spinal cord and the brain.
› Verified 8 days ago